Manipulating IL-10 signalling blockade for better immunotherapy

Cellular Immunology

Volumn 293, Issue 2, 2015, Pages 126-129

  Ni, Guoying ^a   Wang, Tianfang ^b   Walton, Shelley ^b   Zhu, Bin ^c   Chen, Shu ^c   Wu, Xiaolian ^c   Wang, Yuejian ^c   Wei, Ming Q ^a   Liu, Xiaosong ^b,c  

^a GRIFFITH UNIVERSITY   (Australia)

^b UNIVERSITY OF THE SUNSHINE COAST   (Australia)

^c THE FIRST PEOPLE S HOSPITAL OF FOSHAN   (China)

Author keywords

Immunotherapy; Interleukin 10; Vaccine

Indexed keywords

INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 10;

CANCER IMMUNOTHERAPY; CANCER THERAPY; CHRONIC HEPATITIS; CLINICAL PRACTICE; DRUG SAFETY; GENETIC MANIPULATION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW (TOPIC); TUMOR GROWTH; VIRUS INFECTION; ANIMAL; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; IMMUNOLOGY; IMMUNOTHERAPY; T LYMPHOCYTE; VIROLOGY;

ANIMALIA; HEPATITIS C VIRUS;

ANIMALS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-10; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84921047621     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2014.12.012     Document Type: Review

References (75)

1. Ejrnaes M., von Herrath M.G. Cure of chronic viral infection by neutralizing antibody treatment. Autoimmun. Rev. 2007, 6:267-271.
2. Ejrnaes M., von Herrath M.G., Christen U. Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodies. Clin. Dev. Immunol. 2006, 13:337-347.
3. Ha S.J., West E.E., Araki K., Smith K.A., Ahmed R. Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections. Immunol. Rev. 2008, 223:317-333.
4. Freeman G.J., Sharpe A.H. A new therapeutic strategy for malaria: targeting T cell exhaustion. Nat. Immunol. 2012, 13:113-115.
5. Jackson S.R., Berrien-Elliott M.M., Meyer J.M., Wherry E.J., Teague R.M. CD8+ T cell exhaustion during persistent viral infection is regulated independently of the virus-specific T cell receptor. Immunol. Invest. 2013, 42:204-220.
6. Kantzanou M., Lucas M., Barnes E., Komatsu H., Dusheiko G., Ward S., Harcourt G., Klenerman P. Viral escape and T cell exhaustion in hepatitis C virus infection analysed using Class I peptide tetramers. Immunol. Lett. 2003, 85:165-171.
7. Kuchroo V.K., Anderson A.C., Petrovas C. Coinhibitory receptors and CD8 T cell exhaustion in chronic infections. Curr. Opin HIV AIDS 2014.
8. Salek-Ardakani S., Schoenberger S.P. T cell exhaustion: a means or an end?. Nat. Immunol. 2013, 14:531-533.
9. Sumida K., Shimoda S., Iwasaka S., Hisamoto S., Kawanaka H., Akahoshi T., Ikegami T., Shirabe K., Shimono N., Maehara Y., Selmi C., Gershwin M.E., Akashi K. Characteristics of splenic CD8+ T cell exhaustion in patients with hepatitis C. Clin. Exp. Immunol. 2013, 174:172-178.
10. Wang Y., Swiecki M., Cella M., Alber G., Schreiber R.D., Gilfillan S., Colonna M. Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection. Cell Host Microbe 2012, 11:631-642.
11. Wherry E.J. T cell exhaustion. Nat. Immunol. 2011, 12:492-499.
12. Alani R.M., Munger K. Human papillomaviruses and associated malignancies. J. Clin. Oncol. 1998, 16:330-337.
13. Frazer I.H. Immunology of papillomavirus infection. Curr. Opin. Immunol. 1996, 8:484-491.
14. Frazer I.H. The role of the immune system in anogenital human papillomavirus. Australas. J. Dermatol. 1998, 39(Suppl. 1):S5-S7.
15. Kong X., Sun R., Chen Y., Wei H., Tian Z. Gamma delta T Cells drive myeloid-derived suppressor cell-mediated CD8+ T cell exhaustion in hepatitis B virus-induced immunotolerance. J. Immunol. 2014.
16. Tacket C.O., Roy M.J., Widera G., Swain W.F., Broome S., Edelman R. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine 1999, 17:2826-2829.
17. Kapusta J., Modelska A., Figlerowicz M., Pniewski T., Letellier M., Lisowa O., Yusibov V., Koprowski H., Plucienniczak A., Legocki A.B. A plant-derived edible vaccine against hepatitis B virus. FASEB J. 1999, 13:1796-1799.
18. Chisari F.V., Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 1995, 13:29-60.
19. Ding Z., Wei Y. Therapeutic vaccine for melanoma: the untouched grail?. Expert Rev. Vaccines 2007, 6:907-911.
20. Egan M.A. Towards the development of a therapeutic vaccine for the treatment of HIV-1 infection: are we closer than ever?. Expert Rev. Vaccines 2007, 6:289-291.
21. Emens L.A. Roadmap to a better therapeutic tumor vaccine. Int. Rev. Immunol. 2006, 25:415-443.
22. Gissmann L., Nieto K. The therapeutic vaccine: is it feasible?. Arch. Med. Res. 2009, 40:493-498.
23. Hosken N.A. Development of a therapeutic vaccine for HSV-2. Vaccine 2005, 23:2395-2398.
24. Mansour M. Next generation of therapeutic cancer vaccines require smart vaccine design. Hum. vaccin. 2010, 6:959-961.
25. Riedmann E.M. Two therapeutic HPV vaccine candidates successful in phase 1. Hum. Vaccin. Immunother. 2012, 8:1741.
26. Wilson E.B., Brooks D.G. The role of IL-10 in regulating immunity to persistent viral infections. Curr. Top. Microbiol. Immunol. 2011, 350:39-65.
27. Ha S.J., Mueller S.N., Wherry E.J., Barber D.L., Aubert R.D., Sharpe A.H., Freeman G.J., Ahmed R. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J. Exp. Med. 2008, 205:543-555.
28. Nelson D., Fisher S., Robinson B. The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment. J Immunol. Res. 2014, 2014:789069.
29. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004, 10:909-915.
30. Ochsenbein A.F. Principles of tumor immunosurveillance and implications for immunotherapy. Cancer Gene Ther. 2002, 9:1043-1055.
31. Howard M., O'Garra A. Biological properties of interleukin 10. Immunol. Today 1992, 13:198-200.
32. Moore K.W., de Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 2001, 19:683-765.
33. Saraiva M., O'Garra A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol. 2010, 10:170-181.
34. Gabrysova L., Howes A., Saraiva M., O'Garra A. The regulation of IL-10 expression. Curr. Top. Microbiol. Immunol. 2014, 380:157-190.
35. Pitt J.M., Blankley S., McShane H., O'Garra A. Vaccination against tuberculosis: how can we better BCG?. Microb. Pathog. 2013, 58:2-16.
36. Pitt J.M., Stavropoulos E., Redford P.S., Beebe A.M., Bancroft G.J., Young D.B., O'Garra A. Blockade of IL-10 signalling during Bacillus Calmette-Guerin vaccination enhances and sustains Th1, Th17, and innate lymphoid IFN-gamma and IL-17 responses and increases protection to Mycobacterium tuberculosis infection. J. Immunol. 2012, 189:4079-4087.
37. Gonzalez-Lombana C., Gimblet C., Bacellar O., Oliveira W.W., Passos S., Carvalho L.P., Goldschmidt M., Carvalho E.M., Scott P. IL-17 mediates immunopathology in the absence of IL-10 following Leishmania major infection. PLoS patho. 2013, 9:e1003243.
38. Mocellin S., Marincola F.M., Young H.A. Interleukin-10 and the immune response against cancer: a counterpoint. J. Leukoc. Biol. 2005, 78:1043-1051.
39. Brooks D.G., Trifilo M.J., Edelmann K.H., Teyton L., McGavern D.B., Oldstone M.B. Interleukin-10 determines viral clearance or persistence in vivo. Nat. Med. 2006, 12:1301-1309.
40. Brooks D.G., Lee A.M., Elsaesser H., McGavern D.B., Oldstone M.B. IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J. Exp. Med. 2008.
41. Ejrnaes M., Filippi C.M., Martinic M.M., Ling E.M., Togher L.M., Crotty S., von Herrath M.G. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J. Exp. Med. 2006, 203:2461-2472.
42. Liu X.S., Xu Y., Hardy L., Khammanivong V., Zhao W., Fernando G.J., Leggatt G.R., Frazer I.H. IL-10 mediates suppression of the CD8 T cell IFN-gamma response to a novel viral epitope in a primed host. J. Immunol. 2003, 171:4765-4772.
43. Liu X.S., Dyer J., Leggatt G.R., Fernando G.J., Zhong J., Thomas R., Frazer I.H. Overcoming original antigenic sin to generate new CD8 T cell IFN-gamma responses in an antigen-experienced host. J. Immunol. 2006, 177:2873-2879.
44. Liu X.S., Leerberg J., MacDonald K., Leggatt G.R., Frazer I.H. IFN-gamma promotes generation of IL-10 secreting CD4+ T cells that suppress generation of CD8 responses in an antigen-experienced host. J. Immunol. 2009, 183:51-58.
45. Chen S., Wang X., Wu X., Wei M.Q., Zhang B., Liu X., Wang Y. IL-10 signalling blockade at the time of immunization inhibits Human papillomavirus 16 E7 transformed TC-1 tumour cells growth in mice. Cell. Immunol. 2014, 290:145-151.
46. Chen J., Ni G., Liu X.S. Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions. Cell. Immunol. 2011, 269:5-9.
47. Bai F., Town T., Qian F., Wang P., Kamanaka M., Connolly T.M., Gate D., Montgomery R.R., Flavell R.A., Fikrig E. IL-10 signalling blockade controls murine West Nile virus infection. PLoS pathog. 2009, 5:e1000610.
48. Rigopoulou E.I., Abbott W.G., Haigh P., Naoumov N.V. Blocking of interleukin-10 receptor-a novel approach to stimulate T-helper cell type 1 responses to hepatitis C virus. Clin. Immunol. 2005, 117:57-64.
49. Brooks D.G., Ha S.J., Elsaesser H., Sharpe A.H., Freeman G.J., Oldstone M.B. IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:20428-20433.
50. Garidou L., Heydari S., Gossa S., McGavern D.B. Therapeutic blockade of transforming growth factor beta fails to promote clearance of a persistent viral infection. J. Virol. 2012, 86:7060-7071.
51. Teijaro J.R., Ng C., Lee A.M., Sullivan B.M., Sheehan K.C., Welch M., Schreiber R.D., de la Torre J.C., Oldstone M.B. Persistent LCMV infection is controlled by blockade of type I interferon signalling. Science 2013, 340:207-211.
52. Wilson E.B., Yamada D.H., Elsaesser H., Herskovitz J., Deng J., Cheng G., Aronow B.J., Karp C.L., Brooks D.G. Blockade of chronic type I interferon signalling to control persistent LCMV infection. Science 2013, 340:202-207.
53. Castro A.G., Neighbors M., Hurst S.D., Zonin F., Silva R.A., Murphy E., Liu Y.J., O'Garra A. Anti-interleukin 10 receptor monoclonal antibody is an adjuvant for T helper cell type 1 responses to soluble antigen only in the presence of lipopolysaccharide. J. Exp. Med. 2000, 192:1529-1534.
54. Vicari A.P., Chiodoni C., Vaure C., Ait-Yahia S., Dercamp C., Matsos F., Reynard O., Taverne C., Merle P., Colombo M.P., O'Garra A., Trinchieri G., Caux C. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. 2002, 196:541-549.
55. Guiducci C., Vicari A.P., Sangaletti S., Trinchieri G., Colombo M.P. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 2005, 65:3437-3446.
56. de Vos van Steenwijk P.J., Ramwadhdoebe T.H., Lowik M.J., van der Minne C.E., Berends-van der Meer D.M., Fathers L.M., Valentijn A.R., Oostendorp J., Fleuren G.J., Hellebrekers B.W., Welters M.J., van Poelgeest M.I., Melief C.J., Kenter G.G., van der Burg S.H. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol. Immunother. 2012, 61:1485-1492.
57. Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., Drijfhout J.W., Wafelman A.R., Oostendorp J., Fleuren G.J., Offringa R., van der Burg S.H., Melief C.J. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin. Cancer Res. 2008, 14:169-177.
58. Kenter G.G., Welters M.J., Valentijn A.R., Lowik M.J., Berends-van der Meer D.M., Vloon A.P., Essahsah F., Fathers L.M., Offringa R., Drijfhout J.W., Wafelman A.R., Oostendorp J., Fleuren G.J., van der Burg S.H., Melief C.J. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 2009, 361:1838-1847.
59. Zheng L.M., Ojcius D.M., Garaud F., Roth C., Maxwell E., Li Z., Rong H., Chen J., Wang X.Y., Catino J.J., King I. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J. Exp. Med. 1996, 184:579-584.
60. Kundu N., Fulton A.M. Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis. Cell. Immunol. 1997, 180:55-61.
61. Tanikawa T., Wilke C.M., Kryczek I., Chen G.Y., Kao J., Nunez G., Zou W. Interleukin-10 ablation promotes tumor development, growth, and metastasis. Cancer Res. 2012, 72:420-429.
62. Fujii S., Shimizu K., Shimizu T., Lotze M.T. Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. Blood 2001, 98:2143-2151.
63. Mumm J.B., Emmerich J., Zhang X., Chan I., Wu L., Mauze S., Blaisdell S., Basham B., Dai J., Grein J., Sheppard C., Hong K., Cutler C., Turner S., LaFace D., Kleinschek M., Judo M., Ayanoglu G., Langowski J., Gu D., Paporello B., Murphy E., Sriram V., Naravula S., Desai B., Medicherla S., Seghezzi W., McClanahan T., Cannon-Carlson S., Beebe A.M., Oft M. IL-10 elicits IFN gamma-dependent tumor immune surveillance. Cancer Cell 2011, 20:781-796.
64. Mumm J.B., Oft M. Pegylated IL-10 induces cancer immunity: the surprising role of IL-10 as a potent inducer of IFN-gamma-mediated CD8(+) T cell cytotoxicity. Bioessays 2013, 35:623-631.
65. Emmerich J., Mumm J.B., Chan I.H., LaFace D., Truong H., McClanahan T., Gorman D.M., Oft M. IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res. 2012, 72:3570-3581.
66. O'Garra A., Redford P.S., McNab F.W., Bloom C.I., Wilkinson R.J., Berry M.P. The immune response in tuberculosis. Annu. Rev. Immunol. 2013, 31:475-527.
67. Terai M., Tamura Y., Alexeev V., Ohtsuka E., Berd D., Mastrangelo M.J., Sato T. Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential. Cancer Immunol. Immunother. 2009, 58:1307-1317.
68. Diaz-Valdes N., Manterola L., Belsue V., Riezu-Boj J.I., Larrea E., Echeverria I., Llopiz D., Lopez-Sagaseta J., Lerat H., Pawlotsky J.M., Prieto J., Lasarte J.J., Borras-Cuesta F., Sarobe P. Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10. Hepatology 2011, 53:23-31.
69. Naiyer M.M., Saha S., Hemke V., Roy S., Singh S., Musti K.V., Saha B. Identification and characterization of a human IL-10 receptor antagonist. Hum. Immunol. 2013, 74:28-31.
70. Kumar N., Hendriks B.S., Janes K.A., de Graaf D., Lauffenburger D.A. Applying computational modeling to drug discovery and development. Drug Discov. Today 2006, 11:806-811.
71. Jorgensen W.L. The many roles of computation in drug discovery. Science 2004, 303:1813-1818.
72. Rennick D.M., Fort M.M. Lessons from genetically engineered animal models. XII. IL-10-deficient (IL-10(-/-) mice and intestinal inflammation. Am. J. Physiol. Gastrointest. Liver physiol. 2000, 278:G829-G833.
73. Spencer D.M., Veldman G.M., Banerjee S., Willis J., Levine A.D. Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterology 2002, 122:94-105.
74. Gaddi P.J., Crane M.J., Kamanaka M., Flavell R.A., Yap G.S., Salazar-Mather T.P. IL-10 mediated regulation of liver inflammation during acute murine cytomegalovirus infection. PloS one 2012, 7:e42850.
75. Oakley O.R., Garvy B.A., Humphreys S., Qureshi M.H., Pomeroy C. Increased weight loss with reduced viral replication in interleukin-10 knock-out mice infected with murine cytomegalovirus. Clin. Exp. Immunol. 2008, 151:155-164.